Loading…
Minerva Neurosciences, Inc. is projected to decline to $4.64 by 2027, a -2% move from its current price of $4.72. NERV is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.51 | $4.72 | $4.93 | -0.06% |
| Jul 14 | $4.42 | $4.71 | $5.02 | -0.11% |
| Jul 15 | $4.36 | $4.71 | $5.09 | -0.17% |
| Jul 16 | $4.30 | $4.71 | $5.15 | -0.22% |
| Jul 17 | $4.26 | $4.71 | $5.21 | -0.28% |
| Jul 18 | $4.21 | $4.70 | $5.25 | -0.33% |
| Jul 19 | $4.17 | $4.70 | $5.30 | -0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.17 | $4.70 | $5.30 | -0.39% |
| Week 2 | $3.96 | $4.68 | $5.54 | -0.77% |
| Week 3 | $3.80 | $4.67 | $5.73 | -1.15% |
| Week 4 | $3.66 | $4.65 | $5.90 | -1.53% |
| Week 5 | $3.55 | $4.63 | $6.04 | -1.91% |
| Week 6 | $3.44 | $4.61 | $6.17 | -2.29% |
| Week 7 | $3.35 | $4.59 | $6.30 | -2.67% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Minerva Neurosciences was incorporated in 2007 and is based in Burlington, Massachusetts.
NERV is currently priced at $4.92 per share and has a market capitalization of $237.6M. It ranks 5505 by market cap. The stock sits near key moving averages, with the SMA50 at $5.22 and the SMA200 at $4.80, providing a context for near-term price positioning.
The 30-day price range runs from $3.54 to $6.83, reflecting near-term volatility within a defined corridor. The long-range outlook from the forecast shows a path from near-term neutrality toward longer-term bullishness, with a 2050 average price of $24.68 and a max of $56.76, supported by a bullish sentiment late in the forecast horizon.
A major floor 29.0% below — a decisive break under it would weaken the trend.
The nearest floor, 12.9% below — buyers have tended to step in here.
The nearest ceiling, 17.6% above — a clean break opens room to run.
A major ceiling 71.0% above — clearing it would confirm fresh momentum.
Key NERV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NERV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.75 | Sell | $4.77 | Sell |
| MA 10 | $4.93 | Sell | $4.79 | Sell |
| MA 20 | $4.67 | Buy | $4.79 | Sell |
| MA 50 | $5.07 | Sell | $5.05 | Sell |
| MA 100 | $5.81 | Sell | $5.18 | Sell |
| MA 200 | $4.85 | Sell | $4.76 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.58 | Neutral |
| Stoch RSI (14) | 47.36 | Neutral |
| CCI (20) | 11.59 | Neutral |
| Williams %R (14) | -57.64 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 8.51 | Buy |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 42.36 | Neutral |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 27.82 | Buy |
| Momentum (10) | 0.61 | Buy |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 4.56 | Buy |
| ADX (14) | 16.28 | Neutral |
| ATR (14) | 0.19 | Info |
The 30-day technical picture is bullish, and the sentiment is listed as BULLISH. RSI14 is 50, with the short-to-medium trend anchored by SMA50 at $5.22 and SMA200 at $4.80. The stock has defined support at $4.11 and resistance at $5.55, providing a framework for near-term price action.
The 30-day range is $3.54 to $6.83, underscoring a band within which price movement may unfold in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.90 | $4.72 | $5.68 | 0% | Neutral | |
| $3.47 | $4.64 | $6.67 | -2% | Neutral | |
| $3.49 | $4.90 | $7.45 | +4% | Neutral | |
| $4.08 | $5.97 | $9.47 | +26% | Bullish | |
| $4.87 | $7.40 | $12.17 | +57% | Bullish | |
| $4.28 | $6.74 | $11.43 | +43% | Bullish | |
| $3.99 | $6.49 | $11.32 | +37% | Bullish | |
| $4.20 | $7.06 | $12.61 | +50% | Bullish | |
| $3.75 | $6.48 | $11.85 | +37% | Bullish | |
| $4.13 | $7.35 | $13.72 | +56% | Bullish | |
| $4.66 | $9.54 | $19.40 | +102% | Bullish | |
| $9.23 | $20.51 | $47.07 | +335% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.90 | $4.72 | $5.68 | +0.00% |
| August 2026 | $3.70 | $4.44 | $5.53 | -5.88% |
| September 2026 | $3.69 | $4.49 | $5.69 | +1.03% |
| October 2026 | $3.83 | $4.70 | $6.05 | +4.76% |
| November 2026 | $3.68 | $4.56 | $5.94 | -3.06% |
| December 2026 | $3.45 | $4.31 | $5.68 | -5.37% |
Click any year to see its month-by-month NERV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NERV could reach as high as $5.68, with a base case around $4.72 and support toward $3.90 — roughly 0% from $4.72. Price action looks broadly range-bound.
Expect NERV to range from $3.47 to $6.67 through 2027. The $4.64 average target implies a -2% move from current prices. That is -2% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The NERV price prediction for 2028 points to an average of $4.90 (low $3.49, high $7.45) — a potential gain of +4% on today's $4.72. Price action looks broadly range-bound.
In 2029, NERV is projected to trade between $4.08 and $9.47, averaging $5.97 — a potential gain of +26% from today's $4.72. That is up +22% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Minerva Neurosciences, Inc.'s 2030 outlook centres on $7.40, within a $4.87 to $12.17 range. That is up +24% on the projected 2029 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2031, NERV could reach as high as $11.43, with a base case around $6.74 and support toward $4.28 — roughly +43% from $4.72. Buyers look set to stay in control over this stretch.
Expect NERV to range from $3.99 to $11.32 through 2032. The $6.49 average target implies a +37% move from current prices. That is -4% versus the projected 2031 average. Momentum favours further upside here.
The NERV price prediction for 2033 points to an average of $7.06 (low $4.20, high $12.61) — a potential gain of +50% on today's $4.72. Buyers look set to stay in control over this stretch.
In 2034, NERV is projected to trade between $3.75 and $11.85, averaging $6.48 — a potential gain of +37% from today's $4.72. That is -8% versus the projected 2033 average. Momentum favours further upside here.
Minerva Neurosciences, Inc.'s 2035 outlook centres on $7.35, within a $4.13 to $13.72 range. That is up +13% on the projected 2034 average. That marks a +56% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NERV could reach as high as $19.40, with a base case around $9.54 and support toward $4.66 — roughly +102% from $4.72. Momentum favours further upside here.
Expect NERV to range from $9.23 to $47.07 through 2050. The $20.51 average target implies a +335% move from current prices. That is up +115% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NERV today (≈ 211.864407 NERV) could be worth
$4,345.49
+$3,345.49 (+335%) by 2050 · US Dollar
Based on the average projected NERV price of $20.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NERVwould be worth at today's price.
$1,000 invested in NERV on Jul 10, 2025 (≈ 609.756103 NERV) would be worth
$2,878.05
+$1,878.05 (+187.8%) today · 2.88× · US Dollar
Based on a NERV entry price of $1.64 vs. today's $4.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.1 | $925.49 | -7.5% |
| 1 month ago | $4.67 | $1,010.71 | +1.1% |
| 3 months ago | $5.51 | $856.62 | -14.3% |
| 6 months ago | $4.32 | $1,092.59 | +9.3% |
| 1 year ago | $1.64 | $2,878.05 | +187.8% |
| All time (5.0y) ago | $16.56 | $285.02 | -71.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NERV forecast.
Our base-case forecast reaches $9.40 around 2040.
Implied market cap at $9.40: $437.93M
The multi-year forecast shifts from NEUTRAL to BULLISH over time. In 2026 the avg price is $4.92 with a NEUTRAL outlook, and 2027 shows an avg of $4.93 with NEUTRAL sentiment, followed by 2028 at an avg of $5.35 still NEUTRAL. Beginning in 2029 the sentiment becomes BULLISH, with 2029 avg $6.71 and ROI 36.5%.
By 2030 the avg rises to $8.37 and ROI 70.1% under a BULLISH outlook.
Further out, 2031 shows an avg of $7.42 (ROI 50.7%), 2032 at $7.20 (ROI 46.3%), and 2033 at $7.98 (ROI 62.2%), with continued BULLISH sentiment. The path continues through 2034 at $7.15 (ROI 45.2%), 2035 at $8.52 (ROI 73.2%), and 2040 at $10.76 (ROI 118.7%), all with a BULLISH bias.
By 2050 the forecast projects an avg of $24.68 (ROI 401.6%) with a max of $56.76 and a sustained BULLISH sentiment. These are estimates, not guarantees, and actual results will depend on a range of factors including clinical outcomes and market conditions.
Tap a question to reveal the answer.
Avg $8.37, min $5.31, max $14.21, ROI 70.1%, sentiment BULLISH.
The forecast shows NEUTRAL for 2026–2028 and BULLISH from 2029 onward, with 2029 avg $6.71 (ROI 36.5%) and 2030 avg $8.37 (ROI 70.1%).
Yes. The 2050 max forecast is $56.76, indicating a potential to exceed $50 within the forecast horizon.
Current price is $4.92 and market capitalization is $237.6M.
The 30-day range is $3.54 to $6.83.
Minerva Neurosciences, Inc. Community Discussion
0Share your Minerva Neurosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.